From China's Labs to Global Hope: Breakthrough Therapies like Lonigutamab for Chronic Hepatitis D, Risutrombopag for Generalized Pustular Psorias

As we step into 2026, the landscape of innovative medicine is evolving at an unprecedented pace, particularly in China, where homegrown breakthroughs are not just addressing local health challenges but are poised to make waves on the global stage. For patients battling rare and debilitating diseases, this surge in commercialization offers a beacon of hope—reminding us that science knows no borders. As an editor from Hong Kong DengYue Medicine, I've always believed that true progress in healthcare stems from a commitment to excellence and innovation, grounded in sustainability and social responsibility. It's about building bridges: ensuring that quality-driven advancements, upheld by integrity and compliance, reach those who need them most, wherever they are in the world. In this piece, we'll explore a few standout candidates from the 20 priority-review blockbuster drugs expected for approval in China this year, focusing on how these therapies could transform lives while highlighting the journey from Chinese innovation to international impact.

Imagine living with chronic hepatitis D, a relentless viral infection that hijacks the liver, leading to fatigue, jaundice, and an increased risk of cirrhosis or liver cancer. For many patients, current treatments fall short, leaving them in a cycle of uncertainty and declining health. Enter lonigutamab (立贝韦塔单抗) from Huahui Anjian—a pioneering monoclonal antibody targeting the hepatitis B virus surface antigen. As the first such therapy submitted for approval in China, it's designed to neutralize the virus more effectively, with phase IIb trials showing superior viral suppression, normalized liver enzymes, and improved liver stiffness compared to controls. What's truly inspiring is its potential global reach: developed amid China's push for innovative biologics, lonigutamab exemplifies how local R&D can address unmet needs worldwide, potentially offering relief to millions in regions where hepatitis D is endemic, like parts of Asia and Africa. For patients, this isn't just a drug; it's a step toward reclaiming normalcy, underscoring the importance of sustainable innovation that prioritizes long-term health outcomes over short-term gains.

Then there's generalized pustular psoriasis (GPP), a severe, flare-up driven skin condition that turns everyday life into a battle against painful pustules, fever, and systemic inflammation. The physical toll is matched only by the emotional one—isolation, stigma, and the fear of unpredictable outbreaks. Risutrombopag (瑞西奇拜单抗) from Huahai Pharma, the first domestically developed IL-36R monoclonal antibody heading for approval, promises rapid relief: pivotal trials demonstrated significant pustule clearance within a week of a single dose, with a favorable safety profile. As China accelerates its biopharma sector, this therapy isn't staying confined to borders; it's part of a broader trend where Chinese innovations are licensing out globally, fostering collaborations that amplify access. Patients worldwide could benefit from this, reflecting a shared commitment to social responsibility—ensuring that breakthroughs born in one nation contribute to global well-being, all while maintaining the highest standards of quality and ethical development.

Shifting to oncology, NTRK fusion-positive solid tumors represent a rare but aggressive challenge, often affecting younger patients and leading to rapid progression despite standard therapies. The journey—endless scans, failed treatments, and the weight of uncertainty—can feel isolating. Anlotinib (安瑞替尼) from Weikaier Pharma, a next-generation TRK inhibitor, targets these fusions with precision, overcoming resistance seen in earlier drugs. Its phase I/II data show strong efficacy in treatment-naïve, resistant, and even brain-metastatic cases, with good tolerability. This drug's story is a testament to China's maturing ecosystem: from concept to potential global export, it highlights how integrity in research and a focus on compliance can drive therapies that cross oceans, offering hope to patients in underserved markets. It's a reminder that innovation thrives when it's sustainable, not just in labs but in its ripple effects on real lives.

Finally, cholangiocarcinoma (bile duct cancer) is a stealthy adversary, often diagnosed late with limited options, leaving patients facing grueling chemo regimens and dim prognoses. Tepotinib (替恩戈替尼) from Yaojie Ankang, a multi-target kinase inhibitor, zeroes in on tumor cells and their microenvironment, with data from ESMO 2025 showing median progression-free survival of over six months and overall survival exceeding 17 months in FGFR-altered cases—outcomes that could redefine standard care. As this therapy eyes approval, its path from Chinese trials to potential international partnerships embodies the global vision: assisting homegrown drugs to venture abroad, not for profit alone, but to fulfill a deeper responsibility toward humanity's collective health.

These examples from the 2026 pipeline—part of a larger wave of 94 anticipated approvals—illustrate China's shift from follower to leader in biopharma. Yet, beyond the science, it's the human element that resonates: the promise of fewer hospital visits, more family moments, and a future unburdened by disease. As we champion these advancements, let's embrace a mindset of collaboration and ethical stewardship, ensuring that every step forward is taken with the patient's voice at heart. For those navigating these conditions, stay informed and connected—hope is not just on the horizon; it's being built right now, from China to the world.